Will New ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Rare Disease Narrative?

• BridgeBio Pharma recently presented clinical trial updates for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) at the European Society of Cardiology Congress 2025, including new data on reduced cardiovascular mortality and sustained clinical benefits from its open-label extension study.
• These disclosures are significant because they showcase pivotal results for the company’s lead drug candidate, which could influence broad perceptions among healthcare professionals and investors regarding BridgeBio's pipeline progress in rare cardiovascular diseases.
• We'll examine how the unveiling of long-term ATTRibute-CM data for acoramidis may impact BridgeBio Pharma's investment narrative and future pipeline expectations.

This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

BridgeBio Pharma Investment Narrative Recap

To own shares in BridgeBio Pharma, investors must be confident in the company's ability to convert promising late-stage clinical data, especially for acoramidis, into both regulatory approvals and lasting commercial success in rare genetic cardiovascular disease. The recent presentation of new long-term results at the ESC Congress 2025 reinforces BridgeBio's most important near-term catalyst, which remains the U.S. FDA decision on acoramidis. However, the concentration on this single pipeline asset continues to highlight the core business risk of over-reliance should clinical outcomes or competitive dynamics shift.

Among the latest announcements, BridgeBio's showcase of Month 30 and 42 data from the ATTRibute-CM open-label extension study at the ESC Congress stands out. This disclosure aligns directly with investor focus on the durability of acoramidis's clinical benefit ahead of regulatory milestones, reinforcing the strength but also the concentration of BridgeBio's investment thesis. Despite these compelling updates, investors should still be aware that...

Read the full narrative on BridgeBio Pharma (it's free!)

BridgeBio Pharma's narrative projects $1.7 billion in revenue and $297.7 million in earnings by 2028. This requires 92.3% yearly revenue growth and a $1.07 billion earnings increase from current earnings of -$776.4 million.

Uncover how BridgeBio Pharma's forecasts yield a $63.81 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Seven individual fair value estimates from the Simply Wall St Community range from US$14.28 to US$311.66 per share. While opinions differ, revenue growth is still projected to be high, but sustained profitability depends on more than acoramidis alone.

Explore 7 other fair value estimates on BridgeBio Pharma - why the stock might be worth less than half the current price!

Build Your Own BridgeBio Pharma Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your BridgeBio Pharma research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free BridgeBio Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BridgeBio Pharma's overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com